Data from the TANDEMM trial show enduring responses with concurrent anti-GPRC5D and anti-BCMA therapy in relapsed/refractory multiple myeloma. Concurrently infusing anti-GPRC5D agent MCARH109 and anti ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results